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Abstract. 
Lung cancer is the leading cause of death from cancer worldwide. Almost 60% of patients 
with non-small cell lung cancer present with metastasis at the time of diagnosis. Without treat-
ment, the median survival for patients with metastatic non-small cell lung cancer is only 3-4 
months. While targeted therapy has improved median overall survival to 12 months and even 
longer in patients with driver mutations, most patients with initial response to targeted agents 
ultimately develop disease progression. On the other hand, several studies have shown resection 
of solitary brain or adrenal metastases may achieve long-term survival in selected patients. 
However, in patients with solitary extra-cranial, extra-adrenal metastases, the results of metas-
tasectomy have rarely been reported. Herein, we report a case of synchronous solitary axillary 
lymph node metastasis from non-small cell lung cancer. Surgical resection of both the primary 
lung tumor and metastasis combined with perioperative chemotherapy achieved prolonged dis-
ease-free survival in this case. To date, the optimal treatment strategy for patients with solitary 
distant lymph node metastases and resectable primary lung tumors has not been established. 
The addition of metastasectomy to primary lung cancer surgery may provide a chance for 
long-term survival for such patients. 
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中文摘要 
  肺癌位居全世界癌症死亡原因之第一位。約 60%非小細胞肺癌病患診斷時已發生轉
移。轉移性非小細胞肺癌病患未治療的中位數存活期僅約 3 至 4 個月。即使標靶治療用
於部分具有突變基因的病患可延長總存活期至 12 個月甚至更長，但多數起初對於標靶治
療有反應的病患最終疾病仍惡化。另一方面，部分研究指出手術切除轉移病灶對於單一
腦部或腎上腺轉移的病患可能達成長期存活。但對於其它位置單一轉移的病患，轉移病
灶切除的效果很少被提及。我們在這裡提出一個非小細胞肺癌合併同時性單一腋下淋巴
節轉移的臨床案例。經同時手術切除原發性肺腫瘤及轉移病灶後，這個案例達到延長的
無疾病存活。目前針對非小細胞肺癌原發處可切除但併有單一遠端淋巴節轉移的最佳治
療策略尚未確定。轉移病灶切除配合原發肺腫瘤手術有機會延長此類病患的存活期。 
 
關鍵字: 非小細胞肺癌、單一轉移、腋下淋巴節轉移、轉移病灶切除 
 
INTRODUCTION 
It is recognized worldwide that lung cancer is the 
leading cause of cancer death [1]. Approximately 80% 
of lung cancers are non-small cell lung cancers 
(NSCLC) [2], and almost 60% of patients with 
NSCLC present with metastatic disease at diagnosis 
[3]. Metastatic NSCLC used to be considered as an 
incurable disease. Conventional cisplatin-based chem-
otherapy was shown to result in modest benefit with a 
median overall survival of 8-11 months [4]. Previous 
studies have shown that subgroups of patients with 
metastatic NSCLC benefit from novel targeted agents, 
such as epidermal growth factor receptor (EGFR)- 
tyrosine kinase inhibitors, and inhibitors against ana-
plastic lymphoma kinase (ALK) gene rearrangement 
or ROS-1 gene rearrangement products, and therefore 
achieve improved survival [5,6]. Most patients with 
initial response to targeted agents, however, ultimately 
develop disease progression [7]. Long-term survival 
for patients with metastatic NSCLC remains elusive in 
the era of novel targeted therapy. Therefore, it is 
worth noting that selected patients with solitary me-
tastases may benefit from surgical resection. A grow-
ing size of literature has shown selected patients with 
primary resectable NSCLC and solitary brain metas-
tases can achieve long-term survival following metas-
tasectomy [8-10]. Similarly, local radical therapy of 
solitary adrenal metastasis from NSCLC has produced 
long-term survivors when radical resection of the pri-
mary lung tumor is possible [11-14]. However, in pa-
tients with solitary extra-cranial, extra-adrenal metas-
tases from NSCLC, the results of surgical resection 
have rarely been reported. Herein, we report a case of 
synchronous solitary axillary lymph node metastasis 
from NSCLC, who achieved prolonged disease-free 
survival of at least 24 months after surgical resection 
combined with perioperative chemotherapy. 
 
CASE REPORT 
A 63-year-old man with a smoking history of 20 
pack-years presented to our hospital with fatigue and 
right axillary lymphadenopathy. The patient had been 
well until approximately 3 months before presentation. 
He had a common cold, fatigue and a fixed, non-  
tender nodule in the right axilla. Over the next two 
months, the nodule gradually enlarged and fatigue 
persisted. Two weeks prior to presentation, he visited 
a local hospital, where ultrasonography showed an 
irregular-shaped, hypoechoic and homogeneous nod-
ule, approximately 1.5 cm in diameter, in the right 
axilla. There were no abnormal lymph nodes in the 
cervical or supraclavicular region. Excisional biopsy  
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Figure 1. Positron-emission tomography/computed tomography at diagnosis (A and B) and after preoperative 
chemotherapy (C and D) 
 
 
of the right axillary lymph node was performed, and 
the specimen reportedly showed metastatic adenocar-
cinoma. Immunohistochemical staining results were 
positive for CK7, but negative for ER, PR, HER2/neu, 
CDX-2, CK20, TTF-1 and PSA. The patient was then 
referred to our hospital for further survey. 
He reported no history of fever, weight loss, or 
chronic cough. On physical examination there was a 
firm, tender lump in the right axilla. The serum level 
of carcinoembryonic antigen (CEA) was normal (1.36 
ng per milliliter). Whole-body positron-emission to-
mography (PET) in conjunction with computed to-
mography (CT), performed 2 weeks after excisional 
biopsy of the right axillary lymph node, revealed a 
tumor, 4.3 cm in diameter, with intense uptake of 
fluorodeoxyglucose (FDG) in the lower lobe of the 
right lung, with pleural traction (Figure 1A); and a 
nodule with peripheral uptake of FDG in the right ax-
illa (Figure 1B). The magnetic resonance imaging 
(MRI) of the brain showed no tumors. CT-guided fine 
needle aspiration and core biopsy of the lung tumor 
was performed. Pathological examination of the bi-
opsy specimens showed lung parenchyma with infil-
trating adenocarcinoma cells in acinar (40%) and solid 
(60%) growth patterns, poorly differentiated. The tu-
mor cells were immunoreactive for CK7, but non- 
reactive for CK20, TTF-1 and CDX-2 stains. Fur-
thermore, the tumor cells were negative for EGFR 
gene mutations or ALK gene rearrangement. The di-
agnosis was adenocarcinoma of the lung, clinical stage 
IV, T2aN0M1b, according to the American Joint 
Committee on Cancer (AJCC) 7th edition of staging 
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system for lung cancer. 
After multidisciplinary team planning, the patient 
was treated with chemotherapy consisting of cisplatin 
(75 mg per square meter) and pemetrexed (500 mg per 
square meter) every three weeks. After three courses 
of chemotherapy, a restaging PET/CT study showed 
the tumor in the lower lobe of the right lung with re-
duction in size and FDG avidity as compared with the 
result of the previous study (Figure 1C); and the right 
axillary node was also apparently decreased in size 
and FDG avidity (Figure 1D). Approximately four 
months after diagnosis, the patient underwent video- 
assisted thoracoscopic surgery (VATS) lobectomy of 
the lower lobe of the right lung, as well as intrap-
ulmonary, ipsilateral peribronchial, ipsilateral hilar, 
ipsilateral mediastinal, subcarinal and ipsilateral axil-
lary lymph node dissection. The pathological exami-
nation of the specimens revealed R0 resection of ade-
nocarcinoma of the lower lobe of the right lung; there 
were no malignant cells in all dissected lymph nodes. 
Consequently, after preoperative chemotherapy and 
radical resection, the pathologic staging for the patient 
became ypT2aN0M0, stage Ib. After surgery, the pa-
tient received additional three courses of adjuvant 
chemotherapy with cisplatin and pemetrexed, the 
same regimen as the preoperative one. The patient 
remained disease-free for more than 24 months after 
radical surgical resection. 
 
DISCUSSION 
Metastatic NSCLC is generally associated with a 
poor prognosis. Without treatment, the median sur-
vival is only 3-4 months [15]. Treatment with system-
ic chemotherapy has been the gold standard, although 
the efficacy is only modest. For patients with specific 
driver mutations, such as EGFR gene mutations, ALK 
gene rearrangement or ROS-1 gene rearrangement, 
targeted therapy has improved median overall survival 
to 12 months and even longer in clinical studies [16]. 
Nevertheless, the development of resistance to target-
ed therapy hampers the achievement of long-term sur-
vival. On the other hand, since surgery provides the 
best opportunity for cure for patients with early-stage 
NSCLC, it has been proposed that metastasectomy 
may be beneficial for patients with solitary metastases 
if the primary lung tumors are also resectable. Indeed, 
several studies have shown a survival benefit from 
resection of solitary brain or adrenal metastases 
[8-14,17-19]. However, there is limited clinical evi-
dence of the benefit of metastasectomy in patients 
with solitary extra-cranial, extra-adrenal metastases. 
Our patient presented with a T2aN0, resectable 
primary lung tumor with solitary axillary lymph node 
metastasis. The diagnosis and staging were confirmed 
by the whole-body PET/CT and pathologic examina-
tion of the specimens from the axillary lymph node 
and the primary lung tumor. Axillary lymph node me-
tastases are occasionally seen in patients with NSCLC 
[20]. However, it is unusual for a primary NSCLC to 
metastasize to a distant lymph node without involving 
regional ones. Le Pimpec Barthes F et al. [21] report-
ed a patient with right axillary lymph node metastasis 
observed 4 months after a right lower lobectomy per-
formed for a T2N0 NSCLC. The patient subsequently 
underwent surgical excision and adjuvant radiotherapy, 
and survived for more than 6 years afterward. Simi-
larly, reported in a case series [22], a patient with a 
T3N1 NSCLC and solitary ipsilateral axillary lymph 
node metastasis underwent surgical resection of both 
the primary tumor and solitary metastasis, and sur-
vived more than 8 years without disease recurrence. In 
addition, another case series [23] including 3 patients 
with synchronous axillary lymph node metastases who 
underwent surgical resection also reported prolonged 
survival. Although the number of cases was small, 
surgical resection of the primary tumors and solitary 
metastases seemed to provide a chance for long-term 
survival for selected patients with solitary axillary 
lymph node metastases and resectable primary 
NSCLC. It is still controversial, however, whether the 
long-term survival actually resulted from metastasec-
tomy. A retrospective study [24] analyzed 94 patients 
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presenting with extrathoracic synchronous solitary 
metastases amenable to resection of the primary lung 
cancer. Of all patients, 69 (73%) underwent metas-
tasectomy. The result showed that induction therapy 
for adenocarcinoma, N0 staging and lobectomy were 
predictive of a better prognosis, but metastasectomy 
was not. 
It is important, but may be difficult, to identify the 
favorable subgroup who will benefit from metas-
tasectomy. Several factors may influence the outcome 
of patients with a solitary metastasis from NSCLC 
who undergo surgical resection of both the primary 
lung tumor and metastasis. Retrospective analyses 
have shown the intra-thoracic disease status is the 
most important predictor of overall survival after sur-
gical resection [25-28]. More specifically, T1 or T2 
disease, N0 disease, and stage I or II disease have 
been reportedly associated with superior outcome 
[26-28]. Other potential prognostic factors include 
other baseline patient characteristics, the site of me-
tastasis, R0 resection of the metastasis and the primary 
lung tumor, and the use of adjuvant therapy, such as 
perioperative chemotherapy or radiotherapy [27]. The 
roles played by these factors in patients with solitary 
metastatic NSCLC remain inconclusive and need to be 
further studied. 
There are certain unsolved issues in our case. First, 
the presence of residual metastatic lymphadenopathy 
after excisional biopsy was only determined by the 
radiologic evaluation. However, the modest FDG up-
take of the right axillary lymph node shown on the 
PET/CT might be due to post-traumatic inflammation 
after biopsy. Second, to date, there have been no es-
tablished principles of lymph node dissection for pa-
tients with NSCLC and distant lymph node metastases. 
We are not sure that the extent of lymph node dissec-
tion was adequate. 
In conclusion, we have reported a patient with 
successful treatment and prolonged survival who pre-
sented with synchronous solitary axillary lymph node 
metastasis from a T2aN0 NSCLC and underwent re-
section of both the primary lung tumor and the metas-
tasis in combination with perioperative chemotherapy. 
While the optimal treatment strategy for patients with 
solitary distant lymph node metastases and resectable 
primary lung tumors has yet to be achieved, the addi-
tion of metastasectomy to primary lung cancer surgery 
may provide a chance for long-term survival for se-
lected patients. 
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